{"id":468,"date":"2018-01-11T06:17:37","date_gmt":"2018-01-11T06:17:37","guid":{"rendered":"http:\/\/victorthemes.com\/themes\/unova\/?page_id=468"},"modified":"2025-01-21T15:57:52","modified_gmt":"2025-01-21T14:57:52","slug":"home","status":"publish","type":"page","link":"https:\/\/oncngs.eu\/","title":{"rendered":"Home"},"content":{"rendered":"

[vc_row overlay_dotted=\u00a0\u00bb\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1586961426227{padding-top: 5% !important;}\u00a0\u00bb][vc_column][vc_single_image image=\u00a0\u00bb1665″ img_size=\u00a0\u00bbfull\u00a0\u00bb alignment=\u00a0\u00bbcenter\u00a0\u00bb css_animation=\u00a0\u00bbfadeIn\u00a0\u00bb]

European Call for the future Next Generation Sequencing (NGS) solutions for cancer<\/h2><\/div>[vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][\/vc_column][\/vc_row][vc_row][vc_column][vc_tta_tabs style=\u00a0\u00bbflat\u00a0\u00bb shape=\u00a0\u00bbround\u00a0\u00bb spacing=\u00a0\u00bb15″ gap=\u00a0\u00bb15″ alignment=\u00a0\u00bbcenter\u00a0\u00bb active_section=\u00a0\u00bb5″ css=\u00a0\u00bb.vc_custom_1737471468655{background-color: #ffffff !important;border-radius: 10px !important;}\u00a0\u00bb][vc_tta_section title=\u00a0\u00bbPre-commercial Procedure\u00a0\u00bb tab_id=\u00a0\u00bb1675843290549-72945d31-2077″][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][vc_column_text el_class=\u00a0\u00bbtimeline\u00a0\u00bb]<\/p>\n

Pre-commercial Procedure<\/h3>\n

OncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers.<\/p>\n

[\/vc_column_text][vc_btn title=\u00a0\u00bbView more\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb color=\u00a0\u00bbgreen\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Ftender%2F|title:contact%20us||\u00a0\u00bb][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbPhase 0″ tab_id=\u00a0\u00bb1675843290576-507cf0ae-099d\u00a0\u00bb][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][vc_column_text]<\/p>\n

Phase 0 : Curiosity Driven Research<\/strong><\/h3>\n
\n
\n
\n
\n

Phase 0 is a preparation stage.<\/strong> Before the opening of the Call for tender, we defined the needs<\/strong> by collecting feedback of the buyer\u2019s group during the OMC (Open Market Consultation)<\/a> and translate them into requirements and specifications<\/strong> to direct analysis and technical dialogue with the industry. The OMC is now closed. A ‘Frequently Asked Questions’ page<\/a> has been created to gather and respond all the questions we received during the OMC. A matchmaking page<\/a> is also available for organisations\u00a0 interested in finding partners to create consortia and jointly participate in the oncNGS PCP tender.<\/p>\n<\/div>\n

The oncONGS call for tenders is closed! <\/strong>Learn more.<\/a> A Suppliers Information Day<\/a> has been organised on the 29 June 2022 (the recording of the webinar is available here<\/a>).<\/p>\n<\/div>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_btn title=\u00a0\u00bbView more\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb color=\u00a0\u00bbgreen\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase-0-curiosity-driven-research%2F|title:contact%20us||\u00a0\u00bb][vc_btn title=\u00a0\u00bboncNGS call for tenders\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb color=\u00a0\u00bbgreen\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fcall-for-tenders%2F|title:contact%20us|target:%20_blank|\u00a0\u00bb][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbPhase I\u00a0\u00bb tab_id=\u00a0\u00bb1675843346957-d86ba0b3-a538″][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][vc_column_text el_class=\u00a0\u00bbtimeline\u00a0\u00bb]<\/p>\n

Phase I : Solution design<\/h3>\n

Following the preparation phase, including the Open Market Consultation<\/a> events, and the release of the oncNGS Call for Tenders, four tenderers got awarded<\/a> with oncNGS framework agreement and Phase 1 contracts. In the Phase 1, suppliers will need to demonstrate the technical, financial and commercial feasibility of the proposed concepts and approaches to meet the procurement requirements.<\/p>\n

Duration: 4 months<\/strong>[\/vc_column_text][vc_btn title=\u00a0\u00bbView more\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb color=\u00a0\u00bbgreen\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase1%2F|title:contact%20us||\u00a0\u00bb][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbPhase II\u00a0\u00bb tab_id=\u00a0\u00bb1675843360807-64610bcd-8730″][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][vc_column_text el_class=\u00a0\u00bbtimeline\u00a0\u00bb]<\/p>\n

Phase II : Prototype development<\/h3>\n

Development of the well outlined and functioning prototypes.<\/p>\n

In phase 2 suppliers will develop working prototype of designed solution and demonstrate its analytical performance.
\nSuppliers will be also be required to deliver the clinical performance assessment protocol of the pre-commercial devices they will perform in Phase 3.<\/p>\n

Overall duration : 15 months – Execution : 12 months<\/strong>[\/vc_column_text][vc_btn title=\u00a0\u00bbView more\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb color=\u00a0\u00bbgreen\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase2%2F|title:contact%20us||\u00a0\u00bb][\/vc_tta_section][vc_tta_section title=\u00a0\u00bbPhase III\u00a0\u00bb tab_id=\u00a0\u00bb1675843372732-b29196d0-9b07″][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][vc_column_text el_class=\u00a0\u00bbtimeline\u00a0\u00bb]<\/p>\n

Phase III : Clinical validation of a limited set of pre-commercial devices<\/strong><\/h3>\n

the functional and technical properties of the selected solutions will be evaluated in an operational environment.
\nMinimum of 2 pre-commercial devices will be deployed.<\/p>\n

Overall duration : 18 months – Execution : 15 months<\/strong>[\/vc_column_text][vc_btn title=\u00a0\u00bbView more\u00a0\u00bb style=\u00a0\u00bbflat\u00a0\u00bb color=\u00a0\u00bbgreen\u00a0\u00bb align=\u00a0\u00bbcenter\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fphase3%2F|title:contact%20us||\u00a0\u00bb][\/vc_tta_section][\/vc_tta_tabs][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb][\/vc_column][\/vc_row][vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb overlay_dotted=\u00a0\u00bb\u00a0\u00bb overlay_color=\u00a0\u00bbrgba(0,0,0,0.81)\u00a0\u00bb][vc_column][vc_empty_space height=\u00a0\u00bb60px\u00a0\u00bb]

About<\/h2><\/div>[vc_column_text el_class=\u00a0\u00bbwhitetxt\u00a0\u00bb]<\/p>\n

The oncNGS consortium groups several buyers in 5 EU countries to challenge the market to develop novel affordable solutions to provide the most advanced NGS tests for cancer patients. We wish to co-develop an EU innovative tender for liquid biopsy diagnostics based on complex NGS-driven DNA profiling within a pre-commercial procurement Horizon-2020 financed project.<\/p>\n

[\/vc_column_text][vc_btn title=\u00a0\u00bbView more\u00a0\u00bb align=\u00a0\u00bbright\u00a0\u00bb link=\u00a0\u00bburl:http%3A%2F%2Foncngs.eu%2Findex.php%2Fabout%2F|title:About%20OncNGS||\u00a0\u00bb][\/vc_column][\/vc_row][vc_row overlay_dotted=\u00a0\u00bb\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1516712463541{padding-top: 10% !important;padding-bottom: 70px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1584019833909{padding-top: 0px !important;}\u00a0\u00bb]

Latest news<\/h2><\/div>\n \n
\n
\n\n \n
\n
\n
\n
\n \"oncNGS\n
2026-03-11<\/div> <\/div>\n
\n

oncNGS final event – 10\/04\/2026<\/a><\/h4>\n

oncNGS final event to explore the future of innovation[…]<\/p>\n

\n by Editorial team<\/a><\/span>\n \n <\/span> <\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n
\n
\n
\n
\n \"Special\n
2025-05-22<\/div> <\/div>\n
\n

Special Communication on oncNGS PCP published in ESMO Open<\/a><\/h4>\n

Improving the Cancer Care with Innovative ctDNA Analysis The[…]<\/p>\n

\n by Editorial team<\/a><\/span>\n \n <\/span> <\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n
\n
\n
\n
\n \"OncNGS\n
2025-01-21<\/div> <\/div>\n
\n

OncNGS enters Phase 3 of the PCP with two innovative solutions for cancer NGS testing<\/a><\/h4>\n

The Pre-Commercial Procurement (PCP) project OncNGS has entered its[…]<\/p>\n

\n by Editorial team<\/a><\/span>\n \n <\/span> <\/span>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n \n <\/section>\n \n\n [vc_empty_space height=\u00a0\u00bb10px\u00a0\u00bb el_id=\u00a0\u00bbcontact\u00a0\u00bb][\/vc_column][\/vc_row][vc_row full_width=\u00a0\u00bbstretch_row\u00a0\u00bb parallax=\u00a0\u00bbcontent-moving\u00a0\u00bb parallax_image=\u00a0\u00bb1806″ overlay_dotted=\u00a0\u00bb\u00a0\u00bb css=\u00a0\u00bb.vc_custom_1594722719216{padding-top: 7% !important;padding-bottom: 6% !important;}\u00a0\u00bb overlay_color=\u00a0\u00bbrgba(0,0,0,0.5)\u00a0\u00bb][vc_column width=\u00a0\u00bb1\/2″ offset=\u00a0\u00bbvc_col-lg-6 vc_col-md-6″]

Get in touch<\/h2><\/div>[\/vc_column][vc_column width=\u00a0\u00bb1\/2″]\n
\n

<\/p>

    <\/ul><\/div>\n
    \n
    \n\n\n\n\n\n\n<\/div>\n